company background image
FAE

Faes Farma BME:FAE Stock Report

Last Price

€3.91

Market Cap

€1.2b

7D

4.3%

1Y

13.0%

Updated

24 Jun, 2022

Data

Company Financials +
FAE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends3/6

FAE Stock Overview

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally.

Faes Farma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Faes Farma
Historical stock prices
Current Share Price€3.91
52 Week High€4.08
52 Week Low€3.07
Beta0.68
1 Month Change-1.26%
3 Month Change5.85%
1 Year Change13.01%
3 Year Change-5.67%
5 Year Change34.36%
Change since IPO242.17%

Recent News & Updates

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Is Faes Farma (BME:FAE) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will be increasing its dividend on the 23rd of December...

Shareholder Returns

FAEES PharmaceuticalsES Market
7D4.3%4.5%1.0%
1Y13.0%10.8%-10.0%

Return vs Industry: FAE exceeded the Spanish Pharmaceuticals industry which returned 7.6% over the past year.

Return vs Market: FAE exceeded the Spanish Market which returned -11.2% over the past year.

Price Volatility

Is FAE's price volatile compared to industry and market?
FAE volatility
FAE Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement3.7%
10% most volatile stocks in ES Market6.9%
10% least volatile stocks in ES Market1.3%

Stable Share Price: FAE is not significantly more volatile than the rest of Spanish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: FAE's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19331,565n/ahttps://faesfarma.com

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.

Faes Farma Fundamentals Summary

How do Faes Farma's earnings and revenue compare to its market cap?
FAE fundamental statistics
Market Cap€1.20b
Earnings (TTM)€88.29m
Revenue (TTM)€448.84m

13.6x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FAE income statement (TTM)
Revenue€448.84m
Cost of Revenue€159.28m
Gross Profit€289.56m
Other Expenses€201.27m
Earnings€88.29m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.29
Gross Margin64.51%
Net Profit Margin19.67%
Debt/Equity Ratio4.0%

How did FAE perform over the long term?

See historical performance and comparison

Dividends

4.4%

Current Dividend Yield

57%

Payout Ratio

Does FAE pay a reliable dividends?

See FAE dividend history and benchmarks
When do you need to buy FAE by to receive an upcoming dividend?
Faes Farma dividend dates
Ex Dividend DateJun 28 2022
Dividend Pay DateJun 30 2022
Days until Ex dividend3 days
Days until Dividend pay date5 days

Does FAE pay a reliable dividends?

See FAE dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is FAE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FAE?

Other financial metrics that can be useful for relative valuation.

FAE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.6x
Enterprise Value/EBITDA9.8x
PEG Ratio5.4x

Price to Earnings Ratio vs Peers

How does FAE's PE Ratio compare to its peers?

FAE PE Ratio vs Peers
The above table shows the PE ratio for FAE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.4x

Price-To-Earnings vs Peers: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the peer average (23.4x).


Price to Earnings Ratio vs Industry

How does FAE's PE Ratio compare vs other companies in the Pharmaceuticals Industry?

Price-To-Earnings vs Industry: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the European Pharmaceuticals industry average (18.2x)


Price to Earnings Ratio vs Fair Ratio

What is FAE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FAE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.6x
Fair PE Ratio16x

Price-To-Earnings vs Fair Ratio: FAE is good value based on its Price-To-Earnings Ratio (13.6x) compared to the estimated Fair Price-To-Earnings Ratio (16x).


Share Price vs Fair Value

What is the Fair Price of FAE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FAE (€3.91) is trading below our estimate of fair value (€6.62)

Significantly Below Fair Value: FAE is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: FAE is poor value based on its PEG Ratio (5.4x)


Discover undervalued companies

Future Growth

How is Faes Farma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


2.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FAE's forecast earnings growth (2.5% per year) is above the savings rate (0.9%).

Earnings vs Market: FAE's earnings (2.5% per year) are forecast to grow slower than the Spanish market (12.6% per year).

High Growth Earnings: FAE's earnings are forecast to grow, but not significantly.

Revenue vs Market: FAE's revenue (2.5% per year) is forecast to grow slower than the Spanish market (4.5% per year).

High Growth Revenue: FAE's revenue (2.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FAE's Return on Equity is forecast to be low in 3 years time (13%).


Discover growth companies

Past Performance

How has Faes Farma performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


16.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FAE has high quality earnings.

Growing Profit Margin: FAE's current net profit margins (19.7%) are higher than last year (18.6%).


Past Earnings Growth Analysis

Earnings Trend: FAE's earnings have grown by 16.5% per year over the past 5 years.

Accelerating Growth: FAE's earnings growth over the past year (20.6%) exceeds its 5-year average (16.5% per year).

Earnings vs Industry: FAE earnings growth over the past year (20.6%) exceeded the Pharmaceuticals industry 17.9%.


Return on Equity

High ROE: FAE's Return on Equity (16.4%) is considered low.


Discover strong past performing companies

Financial Health

How is Faes Farma's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: FAE's short term assets (€293.7M) exceed its short term liabilities (€79.3M).

Long Term Liabilities: FAE's short term assets (€293.7M) exceed its long term liabilities (€24.4M).


Debt to Equity History and Analysis

Debt Level: FAE has more cash than its total debt.

Reducing Debt: FAE's debt to equity ratio has increased from 0.2% to 4% over the past 5 years.

Debt Coverage: FAE's debt is well covered by operating cash flow (372.8%).

Interest Coverage: FAE's interest payments on its debt are well covered by EBIT (3460.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Faes Farma current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


4.37%

Current Dividend Yield

Upcoming Dividend Payment

TodayJun 25 2022Ex Dividend DateJun 28 2022Dividend Pay DateJun 30 20222 days from Ex DividendBuy in the next 3 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: FAE's dividend (4.37%) is higher than the bottom 25% of dividend payers in the Spanish market (2.07%).

High Dividend: FAE's dividend (4.37%) is low compared to the top 25% of dividend payers in the Spanish market (6.06%).


Stability and Growth of Payments

Stable Dividend: FAE's dividend payments have been volatile in the past 10 years.

Growing Dividend: FAE's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonable payout ratio (56.7%), FAE's dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (258.9%), FAE's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.0yrs

Average board tenure


CEO

Faes Farma has no CEO, or we have no data on them.


Board Members

Experienced Board: FAE's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Faes Farma, S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Faes Farma, S.A.
  • Ticker: FAE
  • Exchange: BME
  • Founded: 1933
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €1.197b
  • Shares outstanding: 306.24m
  • Website: https://faesfarma.com

Number of Employees


Location

  • Faes Farma, S.A.
  • Avenida Autonomía 10
  • Leioa
  • 48940
  • Spain

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.